Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Scandinavian ChemoTech AB - Interim report Q1 January – March 2021 Executive Summary of the first quarter

First quarter · Net sales amounted to kSEK 25 (90) · The order book amounted to kSEK 422 at the end of the first quarter · Profit before tax amounted to kSEK -2 785 (-3 464) · Earnings per share amounted to SEK -0,33 (-1,02) · Cash flow from operating activities totaled to kSEK -5 564 (-4 120) Important events during the quarter · ChemoTech receives a final injunction from the European Patent Office that the patent for the Company’s innovation for TSE treatment of skeletal metastases and deep seated tumours will be granted · ChemoTech was added approximately SEK

2020 Bulkers Ltd. (2020) – Notification of flagging

Reference is made to the press release relating to the contemplated secondary placing of shares in 2020 Bulkers Ltd. (the “Company”) dated 3 May 2021. Drew Holdings Ltd (“Drew”) have sold a total of 1,900,000 shares and Ubon Partners AS (“Ubon”) have sold a total of 1,250,000 shares in the Company at a price of NOK 103.00 per share. After the sale, Drew and Tor Olav Troim will hold a total of 5,502,778 shares and Ubon will hold 784,084 shares representing 24.8% and 3.5% of the share capital and voting rights in the Company, respectively. This information is subject to the disclosure

Annual report 2020 for Initiator Pharma A/S

Initiator Pharma’s annual report for 2020 is now available on the company´s home page http://initiatorpharma.com/investors/financial-reports/ For more information about Initiator Pharma, please contact: Claus Elsborg Olesen, CEOTelephone number: +45 6126 0035 E-mail: ceo@initiatorpharma.com About Initiator Pharma Initiator Pharma is a clinical-stage biotechnology company based in Aarhus, Denmark. The company’s main clinical Phase assets are IPED2015, intended for patients with erectile dysfunction, and IP2018, for the treatment of psychogenic erectile dysfunction. The

Trading Statement for 1 January – 31 March 2021

Company Announcement 6/2021 HusCompagniet generates solid growth in both revenue and EBITA in line with expectations. Sales rates were higher than expected, and consequently, sales commissions increased in Q1 2021. The higher than expected sales rate continued in April, leading to an upgrade of the financial outlook for 2021 to a revenue level of DKK 4,100 – 4,250 million and an EBITA of DKK 360-370 million. “I’m very pleased with the strong results for the first quarter of 2021, showing improvements in all of our segments year-on-year, especially in our detached market. The overall

Formica Capital new majority owner of Rototec Group

Formica Capital acquires Rototec Group from Intera Fund II Ky and the company’s management. Rototec is Europe’s largest provider of geoenergy solutions and has shown strong profitable growth through a combination of entrepreneurship and active M&A. Rototec is Formica’s fourth investment within the shift to a globally sustainable energy system. The company’s management will remain as significant minority owners. Rototec is the market leader in geoenergy solutions for mid-sized and large properties, managing Europe’s largest drilling equipment fleet for geoenergy in

Alligator Bioscience and BioArctic enter into research agreement in the neurodegenerative field

Lund, Sweden, May 4, 2021 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research agreement with BioArctic AB, a Swedish research-based biopharma company focusing on disease-modifying treatments and reliable biomarkers and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Under the agreement, Alligator will employ its proprietary antibody generation technologies in collaboration with BioArctic to develop new product candidates.“We are very pleased that BioArctic has recognized the power of

Farxiga approved in the US for CKD

4 May 2021 07:00 BST Farxiga approved in the US for the treatment of chronic kidneydisease in patients at risk of progression with and without type-2 diabetes Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death AstraZeneca's Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US

Concentric AB partners with a global leader in driveline technology to develop a new electric oil pump for advanced start/stop capability

Concentric AB has partnered with a global Tier 1 manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles to develop a new fully electric oil pump for use within their “start/stop” technology. Production will start in 2022 and sales revenues from this new contract are estimated to be worth MSEK 45 over the next five years. Advanced “start/stop” technology will be offered as an option across their entire range of transmissions and will enable a reduction in CO\2\ emissions of up to 6% in urban applications. This new electric oil pump also uses

Moberg Pharma’s Interim report for January – March 2021 to be published on May 11 - Invitation to teleconference

STOCKHOLM, May 4[th], 2021 - On May 11[th], 2021, at 08:00 am (CET), Moberg Pharma AB (OMX: MOB) will present its Interim report for January – March 2021. Investors, analysts and journalists are hereby invited to participate in a teleconference at 3:00 pm (CET) on the same date.The teleconference will be hosted by Moberg Pharmas’s CEO Anna Ljung and VP Finance Mark Beveridge. The presentation will be held in English. Date:             May 11[th], 2021Time:             3:00 pm (CET) To participate in the conference, please dial in on any number below before the start of the call:

Cloetta launches candy containing 50% fruit

Cloetta’s fruit-based candy, which contains 50% fruit, is a major innovation for 2021 that has been launched across markets under the company’s existing local candy brand portfolio. The product delivers on key consumer trends and is an important part of Cloetta’s innovation strategy to drive organic growth and profitability within the Branded packaged product segment.Consumers are increasingly looking for products with more natural ingredients and positive health benefits. However, it is challenging to develop a product that contains a high level of fruit yet meets the consumers’

TYRI invests an additional €197K EUR ($234K USD) in its EMC laboratory "Now all tests can be carried out in house at TYRI – saving time and money"

TYRI, a world leader in lighting for machinery, continues to invest in the future as they now finance an additional €197K to make possible the ability to do more tests in their own in their EMC laboratory in Gothenburg. With the new investment, they are now able to also measure how their work lights are affected by external interference factors such as power lines, cell towers or the electric environment of the vehicle.When TYRI built their EMC laboratory, the aim was to measure whether their lights interfered with other electronic equipment on board a machine. However, the goal was always

Students compete in creating packaging for all five senses in BillerudKorsnäs’ design competition PIDA

What makes a packaging concept not only functional and visually appealing, but also able to interact with our senses when it comes to sound, touch, taste, or smell?  That’s the challenge for this year’s design students in BillerudKorsnäs’ Packaging Impact Design Award, PIDA. A competition aiming to highlight young talents and their ideas – but also to push the development of packaging design even further. This year PIDA offers a new, modern, and digital format, that enables a larger audience to be part of this exciting event.  PIDA stands for innovation, creativity, and youthful curiosity.

Scandi Standard – First quarter presentation

Scandi Standard will publish its report for the first quarter 2021 on Friday, 7 May 2021 at 07.30 CET. Conference call at 08.30 CET The Company will host a conference call for the financial community at 08.30 CET the same day. The conference call will be hosted by Leif Bergvall Hansen, CEO and Julia Lagerqvist, CFO. Dial in numbers: United Kingdom                   0800 640 6441United Kingdom (Local)       020 3936 2999US                                      1 845 213 3398US Toll-Free                        1 855 9796 654Sweden dial-in number:       010 884 80 16

Thailand reopening roadmap goes ahead amid COVID-19 vaccine rollout

Phuket will be the first to lift quarantine for vaccinated foreign tourists from July onwards, followed by at least five other destinations from October   The Tourism Authority of Thailand’s (TAT) roadmap to reopen six major tourist provinces – Phuket, Krabi, Phang Nga, Surat Thani (Ko Samui), Chon Buri (Pattaya) and Chiang Mai – to foreign tourists who have received two doses of COVID-19 vaccine is going ahead as scheduled in line with the country’s COVID-19 vaccination timeline. Phuket will be the first destination to lift quarantine requirements for vaccinated foreign

Invitation to telephone conference for Interim Report January 1 – March 31, 2021

Mekonomen’s Interim Report for the first quarter 2021 will be published on Friday, May 7, at 07:30 a.m CET. A telephone conference will be held on the same day at 09:00 a.m CET in English. Mekonomen's President and CEO Pehr Oscarson and CFO Åsa Källenius will present the results and respond to questions at the English speaking conference. The presentation material will be available from 8:00 a.m CET on May 7, at www.mekonomen,com under the heading Investors/IR Presentations.   Click this link

Adapteo Q1: A strong start to 2021

Adapteo Plc Regulatory press release 04 May 2021 at 8:00 a.m.CEST January-March 2021 · Acquisition of Stord Innkvartering completed on 29 January 2021. · Rental sales amounted to EUR 39.0 (31.5 in Q1 2020) million. In constant currencies, rental sales increased by 20%. Organic growth (“Old Adapteo”) was 5%. · Net sales amounted to EUR 68.2 (49.1) million. In constant currencies, net sales increased by 34%. Organic growth (“Old Adapteo”) was 6%. · Comparable EBITDA was EUR 26.0 (20.4) million. Comparable EBITDA margin was 38.1% (41.6%). · Operating cash flow

Utilization of authorization in Hexagon AB to repurchase own shares due to incentive programme

The Board of Directors of Hexagon AB (publ) has resolved, pursuant to the authorization granted by the Annual General Meeting held on 29 April 2021, to acquire the company’s own shares of Series B on Nasdaq Stockholm. The purpose of the repurchase is to ensure Hexagon’s undertakings in respect of Share Programme 2021/2024 (other than delivery of shares to participants in the incentive programme), including covering social security costs.Acquisition may be made of maximum 850,000 Series B shares (before the share split resolved upon by the Annual General Meeting). After the share split 7:1

IRRAS AB publishes Interim Report for the period January to March 2021

Meaningful Commercial Acceleration Seen Globally ”During Q1, the global installed base for IRRAS products increased; the total number of IRRAflow systems increased from 73 to 84 and Hummingbird systems grew from 5 to 9.  An increase in the number of systems shipped is important, but it is more critical to convert evaluations into revenue-generating commercial customers. During the quarter, two influential US comprehensive stroke centers, Buffalo General Medical Center and West Virginia University, placed commercial disposable stocking orders for IRRAflow. The contracts signed by these

Finnpark has selected YIT as the developing partner for the Tampere Travel and Service Centre (Tampereen Asemakeskus) area that it owns

YIT CORPORATION Press Release May 4, 2021, at 09:00The Travel and Service Centre is an integral part of the Five-Star City Centre development programme in Tampere. Tampere city centre will be significantly reformed by 2030. Finnpark has selected YIT as its partner for developing and implementing the Tampere Travel and Service Centre owned by it. Companies will next begin to work on a functional concept for the area, which is situated in the address Rautatienkatu 25–27 in the heart of Tampere, as well as the related block and design solutions, which can be utilised in the zoning and

Zengun’s Annual and Sustainability Report 2020 is published

Zengun’s Annual and Sustainability Report for 2020 is now available in English language version on the company’s website as a pdf-document. Please visit www.zengun.se. For more information, please contact: Mick Salonen Högberg, CEO +46 (0) 70 569 66 73Stefan Lindh, CFO +46 (0) 70 383 16 07 This is the type of information that Zengun is obligated to disclose pursuant to the Securities Market Act. The information was issued for publication at 08:00 CET on May 4, 2021.

Sobi publishes report for the first quarter 2021

Swedish Orphan Biovitrum AB (publ)  (Sobi™) today announces its results for the first quarter 2021. Total revenue amounted to SEK 3,661 M, a decrease of 13 per cent at CER compared with the same period 2020. EBITA was SEK 1,484 M, resulting in an EBITA margin of 41 per cent. January – March · Total revenue of SEK 3,661 M (4,639), -21 per cent and -13 per cent at CER · EBITA[1 ]was SEK 1,484 M (2,173), with an EBITA margin[1] of 41 per cent (47) · Earnings per share (EPS) before dilution of SEK 2.36 (4.02) · Haematology sales were SEK 1,877 M (2,394),

SciBase submits first reimbursement application to CMS in Florida

STOCKHOLM, SWEDEN, — May 4, 2021 – SciBase Holding AB (“SciBase”) [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders,  announced today that an application for Medicare coverage of the Nevisense procedure has been submitted in Florida.In October 2020, SciBase was granted a Category III CPT® (CPT III) code from the American Medical Association (AMA) for the Nevisense melanoma detection test. This was the first step in the process to receive reimbursement coverage in the U.S. The application submission for Medicare coverage in Florida marks an

Vicore starts collaboration with Alex Therapeutics to develop new digital therapeutic for patients with IPF

· Webinar will be held today at 15:00 CET (9:00 am EST) · Digital therapeutics expert Jessica Shull joins Vicore to drive DTx program Gothenburg, May 4, 2021 - Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the signing of an agreement with Alex Therapeutics AB for the development and clinical validation of a digital therapeutic (DTx) built on the “Alex DTx Platform”. Vicore will hold a webinar at 15:00 CET (9 AM EST) today to outline

SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version

Lund, Sweden, May 4, 2021. SynAct Pharma AB ("SynAct") today announced that based upon the encouraging results seen in part 1 of the phase 2 clinical study BEGIN of AP1189, the company has decided to increase the study size in an effort to demonstrate statistical significance in the trial.Topline data from part 1 of the BEGIN study with AP1189 in early rheumatoid arthristis (RA) demonstrated a 66-74% treatment effect for the 50mg and 100mg dose groups respectively (Part 1 primary endpoint attainment of: placebo - 44%, 50mg - 67% and 100mg – 75%, previously reported in November 2020).

There are no items matching the current filter
There are no more items matching the current filter
Back to top